Award type :
Product Development Award
Product Development Award
Product type :
Therapeutics
Therapeutics
Award year :
2021
2021
Project start date :
09 / 27 / 2021
09 / 27 / 2021
Project end date :
04 / 12 / 2022
04 / 12 / 2022
Project duration (months) :
6
6
Development stage :
Preclinical
Preclinical
Target disease :
Dengue
Dengue
Region served :
Low- and Middle-Income Countries
Low- and Middle-Income Countries
Recipient organization / Country of funding recipient organization :
Daewoong Therapeutics / Republic of Korea
Daewoong Therapeutics / Republic of Korea
Collaborator(s) / Country :
Genecell Biotech / Republic of Korea
Genecell Biotech / Republic of Korea
Funding amount(KRW) :
370,000,000
370,000,000
Daewoong Therapeutics aims to repurpose niclosamide as an intramuscular depot injection effective against all four serotypes of dengue virus. This project assesses the activity of the compounds on dengue serotypes and performs in vivo efficacy studies in a dengue mouse model. The development of these therapeutics against the dengue virus is in response to the lack of available dengue treatments, and would be a complementary option to vaccines.